| Sep 5 |
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 30 |
Nuvectis’ NXP800 gains FDA ODD for cancer treatment
|
| Aug 29 |
Nuvectis gains on FDA’s orphan drug designation for cancer therapy
|
| Aug 29 |
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
|
| Aug 28 |
Positive Signs As Multiple Insiders Buy Nuvectis Pharma Stock
|
| Aug 6 |
Nuvectis Pharma reports Q2 results
|
| Aug 6 |
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
|
| Jul 28 |
Insiders hold 65% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently
|
| May 24 |
Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
|
